Oral Session 2-11C Novel therapies for ALL

[OS2-11C-1] A phase 2 trial of hyper-CVAD plus ofatumumab for newly diagnosed CD20+ acute lymphoblastic leukemia

Koji Sasaki¹, Hagop Kantarjian¹, Farhad Ravandi¹, Naval Daver¹, Tapan Kadia¹, Rita Beatrice Khouri¹, Alvarado Yesid¹, Jan Burger¹, Deborah Thomas¹, Guillermo Garcia-Manero¹, Courtney Dinardo¹, Naveen Pemmaraju¹, Nicholas Short¹, Heather Schroeder¹, Rebecca Garris¹, Prithviraj Bose¹, Nitin Jain¹, Kiran Naqvi¹, William Wierda¹, Srdan Verstovsek¹, Jorge Cortes¹, Marina Konopleva¹, Susan Obrien², Elias Jabbour¹ (1.MD Anderson Cancer Center, Houston, TX, U.S.A., 2.The University of California, Irvine, U.S.A.)